Save time and get answers to complex questions with AI chat
Bivalirudin manufacturer?Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?Quartette side effects?Norcuron generic name?Tenofovir generic patent?
See the DrugPatentWatch profile for semaglutide
Semaglutide’s core U.S. patent (US 8,860,467) expires on December 15, 2028. That patent covers the composition of matter for semaglutide and its use in treating type 2 diabetes and obesity. Several other Novo Nordisk patents that cover formulation, delivery systems, or specific dosage forms will expire in the next couple of years (most ending on December 15 2029 or in 2030), but the key therapeutic patent runs out on 15 December 2028.
Other Questions About Semaglutide :